Press releases
Jun 05, 2019
RhoVac AB receives approval to start clinical phase IIb study in Denmark
Regulatory press release: RhoVac AB (RhoVac) announces today, June 5, 2019, that the Danish Medicines Agency (DMA) has approved RhoVacs clinical trial...[Read more]
May 21, 2019
RhoVac publishes research results prior ASCO's meeting
Regulatory press release: RhoVac announces today, 21st May 2019, that a summary of the collaboration with Lund University has been published prior to...[Read more]
Apr 26, 2019
RhoVac reports positive written response from the FDA regarding recently completed pre-IND meeting
Regulatory press release: RhoVac AB (RhoVac) reports today, on April 26, 2019, that the company has received a written response from the Food and Drug...[Read more]
Announcements
17 January, 2019
RhoVac reports positive interim immune-results in the follow-up phase of company’s phase I/II clinical study
17 December, 2018
RhoVac announces that the first patient completed the follow-up phase of the clinical phase I / II study
14 November, 2018
RhoVac participates in international business conferences in the UK and the United States
Press Releases and Company Announcements published before 1 May 2017 in Swedish only.
RhoVac in Brief
RhoVac undertakes research and development of therapeutic cancer vaccines. The primary candidate, RV001, targets RhoC which is overexpressed in cancer cells with metastatic potential.
Because most cancers form metastases, RV001 can potentially be used to treat a broad range of cancers. RhoVac's concept focuses on eliminating metastatic cancer cells that may escape treatment of the parent tumour via other methods. Because RhoC is not expressed in the parent tumour, the company goal is to use the developed product in combination with another therapy -- specifically, treatment of the parent tumour by e.g. surgery, radiotherapy or chemotherapy together with treatment with the therapeutic cancer vaccine to combat metastasis.
